P940019/S067: WALLSTENT ILIAC RP Endoprosthesis
FDA’s recorded scope: the extension of maximum transfer time between preconditioning cell to sterilization chamber during routine production for Ethylene Oxide(EtO) sterilization
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Boston Scientific Scimed, Inc.. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 6, 2026 to May 6, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NIO appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P940019, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: One Scimed Pl., Maple Grove, MN, 55311. Recorded on P940019/S067, decision dated May 6, 2026.
FDA’s recorded scope: the extension of maximum transfer time between preconditioning cell to sterilization chamber during routine production for Ethylene Oxide(EtO) sterilization
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
WALLSTENT ILIAC RP EndoprosthesisP940019/S067 | Boston Scientific Scimed, Inc. | PMA supplement | May 6, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.